A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer

Alaunos Therapeutics

Status and phase: Completed; Phase 1

Conditions: Advanced Cancer

Treatments: Drug: ZIO-201

Study type: Interventional

Funder types: Industry

Identifiers

NCT00421135

IPM1001

Details and patient eligibility

About

The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced cancer.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Metastatic and /or unresectable disease state after previous standard chemotherapy

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Single Arm

Experimental group

Description:

ZIO-201

Treatment:

Drug: ZIO-201